Lonza gains experienced scientific adviser
Professor Jonathan Knowles has joined Lonza Group in Switzerland as a part-time scientific adviser.
You may also like
Research & Development
![Lonza acquires rights to Nona's TfR1 blood-brain barrier technology and expands strategic collaboration]()
Lonza acquires rights to Nona's TfR1 blood-brain barrier technology and expands strategic collaboration
Nona Biosciences’ BBB technology, combined with Lonza’s biologics development and bioconjugation capabilities, aims to enable development for central nervous system (CNS) therapies
Research & Development
![The IND advantage: why early derisking is a strategic imperative for complex biologics]()
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
![Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies]()
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
![Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation]()
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines
